Can catheter design impact patient safety? That’s the question of a new peer-reviewed study from Medical Components, Inc. (Medcomp), based on a retrospective analysis of 3,546 catheter insertions captured in Truveta Data. Used to deliver life-sustaining dialysis...
Overall GLP-1 prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2025 increased slightly relative to March 2025 (+7.7%). Tirzepatide is now the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and...
The rate of pediatric fluoride prescriptions per all prescriptions decreased by 54.3% from the first quarter of 2022 (5.0 per 1,000 prescriptions) to the second quarter of 2025 (2.3 per 1,000 prescriptions). Across the study period, the 10 US states with lowest...
In this Truveta experts spotlight, Jared Kern and Vidya Venkataraman, PhD explored trends in the use of Rituxan biosimilars between 2018 and 2024. Their analysis of Truveta Data reveals how patient access and switching behavior has evolved over time. Jared Kern is a...
The proportion of patients initiating treatment for multiple sclerosis (MS) with a high efficacy disease-modifying therapy (DMT) more than doubled from 2018 to 2025, reflecting evolving clinical guidelines. Use of oral and injectable therapies showed a gradual decline...
This post kicks off our new series, Truveta experts— a spotlight on the data scientists, researchers, clinicians, and analysts working behind the scenes to drive healthcare research forward with real-world data. Our first contributor is Mantas Dmukauskas, PhD, a...
A new peer-reviewed study from researchers at Saint Luke’s Mid America Heart Institute, Impulse Dynamics, and the Cardiovascular Research Foundation demonstrates the power of real-world data to evaluate device therapies. By evaluating survival outcomes of cardiac...
Thimerosal is a preservative contained in some vaccines, which has been used and considered safe for decades. During the June 2025 ACIP meeting, a presentation and vote on the use of thimerosal is scheduled to take place. During the 2024-2025 respiratory virus season,...
Switching from bio-originator Humira to a biosimilar peaked in April 2024 – the month an important formulary change took effect – and remains higher than 2023, suggesting growing adoption of biosimilars. More than 1 in 8 patients who initiated a biosimilar...
